Riskpilot← Back to searchSign inGet full accessMedTravest IV ApS
APSActiveCVR 44303981Lundhedevej 25AActivities of holding companies · NACE 6421Est. 2023— employees
Revenue 2025
DKK -27K
+7% vs 2024
EBITDA margin
100.0%
-7% vs 2024
Equity ratio
99.9%
Financial strength
Net profit 2025
DKK -17K
+15% vs 2024
| Revenue | DKK -27K | +7% |
| EBITDA | DKK -27K | -7% |
| Net profit | DKK -17K | +15% |
| Total assets | DKK 45,2M | +70% |
| Equity | DKK 45,1M | +70% |
| Employees | — | — |
Legal name
MedTravest IV ApS
CVR number
44303981
Legal form
Anpartsselskab
NACE code
6421 · Activities of holding companies
Founded
15. september 2023
Share capital
DKK 64.379.749
Employees
—
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af direktøren i forening med bestyrelsesformanden eller af to
bestyrelsesmedlemmer i forening.
Company purpose
Virksomhedens formål er at finansiere og investere i MedTrace Pharma A/S (CVR-nr.
36497661) og associerede virksomheder.
Address
Lundhedevej 25A
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2024 | 2025 |
|---|---|---|
| Revenue | -25 | -27 |
| Staff expenses | -0 | -0 |
| EBITDA | -25 | -27 |
| Depreciation & amort. | -0 | -0 |
| EBIT | -25 | -27 |
| Net financials | -0 | 5 |
| Profit before tax | -25 | -22 |
| Tax | -6 | -5 |
| Net profit | -20 | -17 |
| Item | 2024 | 2025 |
|---|---|---|
| Total assets | 26.506 | 45.150 |
| Equity | 26.480 | 45.113 |
| Long-term debt | 0 | 0 |
| Short-term debt | 25 | 37 |
| Total debt | 25 | 37 |
EBITDA margin
-2679000.0%
This company
15.8%
Market median
-16955796% vs market
20242025
Equity ratio
99.9%
This company
38.2%
Market median
+162% vs market
20242025
Return on equity
-0.0%
This company
18.4%
Market median
-100% vs market
20242025
Net profit margin
-1685300.0%
This company
8.1%
Market median
-20806273% vs market
20242025
Asset turnover
-0.00×
This company
1.12×
Market median
-100% vs market
20242025
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20242025
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
CV Management | Management | 2025 |
| Former (1) | ||
PJ Management | Management | 2023 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2023 | |
| Board of Directors | 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 66.67–89.99% | 66.67–89.99% | 2025 | |
| Company | 5–9.99% | 5–9.99% | 2026 | |
| Company | 5–9.99% | 5–9.99% | 2025 | |
| Company | 5–9.99% | 5–9.99% | 2025 | |
| Company | 50–66.65% | 50–66.65% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Hyorakel Invest ApS
MedTravest IV ApS Board members of MedTravest IV ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Peter Juul Kristensen | Management | 0 companies |
| Charlotte Vindfeldt | Management | 0 companies |
| Martin Lund Madsen | Chairman | 0 companies |
| Jonas Koch Nørgaard | Board of Directors | 0 companies |